ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly

Abstract

Pulmonary vascular diseases such as pulmonary embolism and pulmonary hypertension are important and frequently under recognized conditions. This article provides an overview of key highlights in pulmonary vascular diseases from the 2023 ERS congress. This includes insights into disease modification in pulmonary arterial hypertension and novel therapies such as sotatercept, and seralutinib. Exciting developments in our understanding of the mechanisms underpinning pulmonary hypertension associated with interstitial lung disease are also explored. A comprehensive overview of the complex relationship between acute pulmonary embolism and chronic thromboembolic pulmonary hypertension (CTEPH) is provided and our current understanding of the molecular determinants of CTEPH. The importance of multidisciplinary and holistic care cannot be understated, and this article also addresses advances beyond medication, with a special focus on exercise training and rehabilitation.